---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-422929"
form_type: "8-K"
ticker: "TRAX"
cik: "0002091349"
company_name: "First Tracks Biotherapeutics, Inc."
filed_at: "2026-10-15T20:28:55+00:00"
generated_at: "2026-10-15T20:30:03.569987+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# First Tracks Biotherapeutics raises $200M in private placement at $32.75/share

## Summary
- Sells 6,106,870 common shares at $32.75/share for ~$200M gross proceeds; closing expected October 19, 2026, subject to customary conditions.
- Investors include Affinity Asset Advisors, First Light Asset Management, Sirenia Capital, TCGX, Trails Edge Capital, Vestal Point Capital and mutual funds.
- Proceeds intended for general corporate purposes, including clinical development of ANB033, a CD122 antagonist.
- Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities acted as placement agents.
- Shares issued under Section 4(a)(2); resale registration statement due within 30 days of closing. 35,909,814 shares outstanding as of Oct 12, 2026.

## SEC filing metadata
- accession: 0001193125-26-422929
- form_type: 8-K
- ticker: TRAX
- cik: 0002091349
- company_name: First Tracks Biotherapeutics, Inc.
- filed_at: 2026-10-15T20:28:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/0001193125-26-422929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2091349/000119312526422929/trax-20261015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-422929
- JSON: https://secwatch.observer/filing/0001193125-26-422929.json
- Plain text: https://secwatch.observer/filing/0001193125-26-422929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.